Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 15, 2022

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

GlobeNewswire November 9, 2022

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 1, 2022

Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

GlobeNewswire October 27, 2022

Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.

GlobeNewswire October 27, 2022

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

GlobeNewswire October 24, 2022

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET

GlobeNewswire October 19, 2022

Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

GlobeNewswire October 11, 2022

Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant(TM) (diazepam) Buccal Film for European and MENA Markets

GlobeNewswire September 28, 2022

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

GlobeNewswire September 27, 2022

Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

GlobeNewswire September 12, 2022

Aquestive Therapeutics to Participate in Two Investor Conferences in September

GlobeNewswire August 31, 2022

Aquestive Therapeutics Receives FDA Tentative Approval for Libervant(TM) (diazepam) Buccal Film

GlobeNewswire August 31, 2022

Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

GlobeNewswire August 10, 2022

Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 2, 2022

Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference

GlobeNewswire July 26, 2022

Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8:00 a.m. ET

GlobeNewswire July 20, 2022

Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film

GlobeNewswire July 11, 2022

Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

GlobeNewswire June 15, 2022

Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering

GlobeNewswire June 8, 2022